State Street’s Starling Oncology STLN Stock Holding History

State Street’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.43M	Buy	1,552,917 +91,463	+6%	+$384K	﹤0.01%	2771
2026 Q1	$4.49M	Buy	1,461,454 +109,830	+8%	+$337K	﹤0.01%	3002
2025 Q4	$4.81M	Buy	1,351,624 +221,599	+20%	+$822K	﹤0.01%	3012
2025 Q3	$3.94M	Buy	1,130,025 +483,768	+75%	+$1.66M	﹤0.01%	3084
2025 Q2	$1.32M	Buy	646,257 +544,957	+538%	+$1.36M	﹤0.01%	3428
2025 Q1	$115K	Hold	101,300	–	–	﹤0.01%	3944
2024 Q4	$31.3K	Hold	101,300	–	–	﹤0.01%	4183
2024 Q3	$33.1K	Hold	101,300	–	–	﹤0.01%	4163
2024 Q2	$46.6K	Hold	101,300	–	–	﹤0.01%	4154
2024 Q1	$160K	Hold	101,300	–	–	﹤0.01%	3924
2023 Q4	$207K	Buy	101,300 +23,300	+30%	+$40.4K	﹤0.01%	3895
2023 Q3	$109K	Buy	78,000 +6,000	+8%	+$6.21K	﹤0.01%	4092
2023 Q2	$39.6K	Sell	72,000 -347,621	-83%	-$184K	﹤0.01%	4474
2023 Q1	$284K	Buy	419,621 +644	+0.2%	+$822	﹤0.01%	3943
2022 Q4	$691K	Buy	418,977 +130,850	+45%	+$367K	﹤0.01%	3657
2022 Q3	$1.33M	Buy	288,127 +89,500	+45%	+$526K	﹤0.01%	3527
2022 Q2	$1M	Buy	198,627 +167,527	+539%	+$1.22M	﹤0.01%	3633
2022 Q1	$222K	Buy	+31,100	New	+$210K	﹤0.01%	4342

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

State Street's STLN Position: Q2 2026 in Review

State Street increased its Starling Oncology (STLN) stake by 6.3% in Q2 2026, buying an estimated $384K and bringing the position to 1,552,917 shares worth $8.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

State Street first reported a position in STLN in Q1 2022 and has held it in 18 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

State Street held 1,552,917 shares of Starling Oncology worth $8.43M as of Q2 2026.
State Street bought 91,463 Starling Oncology shares in Q2 2026, an estimated $384K.
Starling Oncology made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2771 holding.
State Street first reported a position in Starling Oncology in Q1 2022 and has held it in 18 quarters since.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.